JonathanEliotBenjaminMD

Oncology • South San Francisco, CA

Vice President for Clinical Research Atreca

Join to view full profile

Dr. Benjamin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Benjamin's full profile

Already have an account?

Office
Atreca, Inc.
450 East Jamie Court
South San Francisco, CA 94080
Phone+1 650-453-5275

Education & Training

University of California (San Francisco)Residency, Internal Medicine, 2001 - 2004
New York University School of MedicineClass of 2001

Certifications & Licensure

CA State Medical License 2003 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Start of enrollment: 2009 May 01
Completed
Phase 2
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) Start of enrollment: 2010 Nov 01
Completed
Phase 2
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders Start of enrollment: 2011 Mar 01
Completed
Phase 2
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell Start of enrollment: 2011 Dec 01
Completed
Phase 1, Phase 2
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Start of enrollment: 2012 Jul 01
Completed
Phase 2
Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia Start of enrollment: 2014 Jan 03
Completed
Phase 2
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102) Start of enrollment: 2013 Dec 16
Completed
Phase 2
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL Start of enrollment: 2017 Jan 23
Completed
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

16 citations
Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms.
Rupa Narayan, Jonathan Benjamin, Omid Shah, Lu Tian, Keri Tate
Biology of Blood and Marrow Transplantation. 2019-07-01
511 citations
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio, Albrecht Reichle, Carlos Graux
Blood. 2018-04-05
19 citations
Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia.
Max S. Topp, M Stelljes, Gerhard Zugmaier, Phillip Barnette, Leonard T. Heffner
Leukemia. 2018-02-01

Press Mentions

13 Discoveries in the Last Year Have Fundamentally Altered Our Understanding of Human HistoryDecember 11th, 2020

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member
American Society for Blood and Marrow Transplantation
Member

Industry Relationships

Vice President Clinical Research, Atreca, Inc2017 - Present
Medical Director, Amgen2014 - 2017